Floatz logo

Niraparib

Glioma

University of OklahomaSmall moleculePhase 2Active
CCC
55/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
73/ 100

Competitive context

95 Active assets in the Glioma cohort.

Asset / SponsorPhaseRating
Olutasidenib
Rigel Pharmaceuticals
Phase 4BBB
Valproic Acid
Medical University of South Carolina
Phase 2B
Irinotecan
Kailin Yang, MD, PhD
Phase 3B
DIANHYDROGALACTITOL
Kintara Therapeutics, Inc.
Phase 2B
Cyclophosphamide
Essen Biotech
Phase 2B

View all 50 →

Same molecule, other indications

Niraparib is also rated in:

breast carcinomaDormant
BB
Indicative ·
67 / 100
View asset →
ovarian neoplasmDormant
BB
Indicative ·
66 / 100
View asset →
ovarian carcinomaDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →